FOI Request
- Disclosure ID
- FOI/02310
- Request Date
- March 26, 2018
- Subject
- NOAC's
- Description
- In your trust how many patients in the last 3* months have been treated for NVAF (Non-Valvular Atrial Fibrillation), with the drugs below:
Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Warfarin - How many patients in the last 3* months have been treated for DVT (Deep Vein Thrombosis), with the drugs below:
Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Warfarin
Heparin - How many patients in the last 3* months have been treated for PE (Pulmonary Embolism), with the drugs below:
Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Warfarin - How many patients in the last 3* months have been treated for the prevention of recurrent DVT (Deep Vein Thrombosis) or prevention of recurrent PE (Pulmonary Embolism) with the drugs below:
Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Warfarin
*Latest 3 months that you have available
- In your trust how many patients in the last 3* months have been treated for NVAF (Non-Valvular Atrial Fibrillation), with the drugs below:
- Response
- We do not routinely record the requested data and to determine if we hold this information would require a manual trawl through paper records. This would constitute a disproportionate effort to retrieve and would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).
We are able to provide the following number of patients have had these medications dispensed directly to them in the last 3 months. Additional patients will also have had medicines for these indications from ward stock but we are also unable to obtain this data.
Apixaban- 352 patients
Dabigatran – 45 patients
Endoxban – 83 patients
Rivaroxaban – 121 patients
Warfarin – 381 patients
LMWH- Dalteparin – 567 patients - We do not routinely record the requested data and to determine if we hold this information would require a manual trawl through paper records. This would constitute a disproportionate effort to retrieve and would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).
We are able to provide the following number of patients have had these medications dispensed directly to them in the last 3 months. Additional patients will also have had medicines for these indications from ward stock but we are also unable to obtain this data.
Apixaban- 352 patients
Dabigatran – 45 patients
Endoxban – 83 patients
Rivaroxaban – 121 patients
Warfarin – 381 patients
LMWH- Dalteparin – 567 patients - We do not routinely record the requested data and to
determine if we hold this information would require a
manual trawl through paper records. This would
constitute a disproportionate effort to retrieve and
would exceed 18 hours. This information is therefore
exempt on the grounds of cost (Section 12(1)).
We are able to provide the following number of patients
have had these medications dispensed directly to them
in the last 3 months. Additional patients will also have
had medicines for these indications from ward stock
but we are also unable to obtain this data.
Apixaban- 352 patients
Dabigatran – 45 patients
Endoxban – 83 patients
Rivaroxaban – 121 patients
Warfarin – 381 patients
LMWH- Dalteparin – 567 patients - We do not routinely record the requested data and to
determine if we hold this information would require a
manual trawl through paper records. This would
constitute a disproportionate effort to retrieve and
would exceed 18 hours. This information is therefore
exempt on the grounds of cost (Section 12(1)).
We are able to provide the following number of patients
have had these medications dispensed directly to them
in the last 3 months. Additional patients will also have
had medicines for these indications from ward stock
but we are also unable to obtain this data.
Apixaban- 352 patients
Dabigatran – 45 patients
Endoxban – 83 patients
Rivaroxaban – 121 patients
Warfarin – 381 patients
LMWH- Dalteparin – 567 patients
- We do not routinely record the requested data and to determine if we hold this information would require a manual trawl through paper records. This would constitute a disproportionate effort to retrieve and would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).